Results from a pilot clinical trial evaluating the safety and feasibility of repeated focused ultrasound-induced blood–brain barrier (BBB) opening combined with the monoclonal antibody drug Avastin ...

For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.

(MENAFN- EIN Presswire) EINPresswire/ -- The global Anti-Vascular Endothelial Growth Factor (Anti-VEGF) market is poised for significant growth in the coming years. Valued at US$ 25.2 billion in 2025, ...

We issued the final draft guidance document (FDG) for this appraisal in December 2025. We received a request to correct factual errors which has resulted in amendments to section 1 of the FDG. We have ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new ...

A long-standing debate over the most effective treatment for prevalent forms of colorectal cancer — the world’s third most diagnosed cancer — was finally settled in June 2022. The much-anticipated ...